mRCC Control Seen After Immunotherapy Is Stopped – Clinical Oncology News
|
mRCC Control Seen After Immunotherapy Is Stopped
Clinical Oncology News mRCC Control Seen After Immunotherapy Is Stopped. Orlando, Fla.—Patients with mRCC who respond to programmed death 1/programmed death ligand 1 checkpoint inhibitor therapy can have persistent clinical benefit, even after treatment discontinuation. |
